Trial intelligence / Profile preview

Niraparib plus Bevacizumab in Platinum-Resistant Ovarian Cancer

NCT04556071Phase 2Unknown

Start
Nov 2020
Primary completion
Mar 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Status: unknown.

02

Drugs

niraparib
03

Conditions

ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)

Beyond the preview

Go deeper on NCT04556071.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04556071.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call